QPPV.COM KNOWLEDGE ASSESSMENT

Mosunetuzumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Mosunetuzumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best explains why the authorised disease context is relevant to causality assessment for cytopenias?

Relapsed or refractory follicular lymphoma has no effect on blood counts Marrow involvement and cumulative prior treatment can independently reduce counts and complicate attribution to mosunetuzumab Cytopenias occur only when CD20 is absent Prior therapy affects efficacy but never affects safety interpretation

Question 2 of 10 A pharmacovigilance reviewer is comparing mosunetuzumab with autologous CAR-T therapy. Which distinction is most accurate based on the article?

Mosunetuzumab requires patient-specific cell collection and manufacturing before administration Mosunetuzumab is an off-the-shelf antibody format that redirects existing T cells without patient-specific cell manufacturing CAR-T therapy does not involve T-cell-mediated cytotoxicity Mosunetuzumab permanently genetically modifies the patient's T cells

Question 3 of 10 Which combination of information is most relevant to distinguishing laboratory TLS from clinical TLS or another cause of renal deterioration?

Only the patient's age and treatment centre Serial uric acid, potassium, phosphate, calcium and creatinine values together with tumour burden and clinical consequences The presence of a previous infusion reaction without laboratory data A single isolated lymphocyte count obtained before treatment

Question 4 of 10 What is the principal pharmacovigilance value of documenting the exact step-up dose that preceded a CRS event?

It identifies whether the patient received a subcutaneous or intramuscular formulation It allows assessment of temporal relationship to the exposure sequence associated with greatest early CRS susceptibility It proves that the event was caused by mosunetuzumab rather than infection It determines whether the patient had follicular lymphoma

Question 5 of 10 Which finding would most strongly support a clinically significant CRS assessment rather than an isolated nonspecific fever?

Fever accompanied by hypotension or hypoxia after a documented mosunetuzumab dose A mild headache occurring several weeks before treatment Stable chronic anaemia without a change in symptoms An early radiologic increase in lymph-node size without systemic symptoms

Question 6 of 10 Which description best captures mosunetuzumab's primary pharmacologic mechanism?

It inhibits a tumour-cell kinase to prevent malignant B-cell proliferation It binds CD20 and CD3 simultaneously, bringing T cells into contact with CD20-positive B cells It blocks complement activation against CD20-positive cells It replaces a patient's T cells with genetically modified autologous cells

Question 7 of 10 Why does conditional marketing authorisation increase the importance of ongoing benefit-risk review for mosunetuzumab?

Conditional authorisation means the mechanism is not known Further evidence and periodic reassessment may change conclusions about benefit, sequencing and exposed populations Conditional authorisation removes the requirement for current product information It means safety monitoring is needed only before the first marketing authorisation

Question 8 of 10 Which statement best describes the relationship between mosunetuzumab's efficacy and its characteristic acute immune toxicity?

They arise from entirely unrelated pharmacologic mechanisms Both result from T-cell redirection: effective cytotoxic engagement can also generate cytokines and systemic immune effects Efficacy depends on complement, whereas CRS depends only on renal impairment CRS indicates that CD20 targeting has failed

Question 9 of 10 Which set of variables is most appropriate for a high-quality mosunetuzumab case report involving suspected CRS?

Dose number, step-up stage, onset timing, fever, blood pressure, oxygen requirement, grade, infection work-up, treatment and outcome Only the patient's tumour histology and the date of the next clinic appointment Only the presence or absence of fever, without vital signs or treatment details The product name without dose, batch, clinical course or competing diagnoses

Question 10 of 10 Which feature of CD20 makes it a useful therapeutic target in follicular lymphoma while permitting eventual B-cell regeneration?

CD20 is expressed exclusively on haematopoietic stem cells CD20 is found on many malignant and mature normal B cells but not on haematopoietic stem cells CD20 is expressed only after B cells become plasma cells CD20 is present only on T cells within the tumour microenvironment

Mosunetuzumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings